Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axcella Health Inc. - Common Stock (NQ:AXLA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axcella Health Inc. - Common Stock

< Previous 1 2 Next >
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
From Axcella Therapeutics
Via Business Wire
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
From Axcella Therapeutics
Via Business Wire
Axcella Announces Upcoming Investor Conference Presentation
From Axcella
Via Business Wire
Axcella Health Inc. (NASDAQ: AXLA) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
Via Investor Brand Network
Topics Derivatives
Axcella Announces Upcoming Investor Conference Presentation
From Axcella
Via Business Wire
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
From Axcella
Via Business Wire
Axcella Reports Second Quarter Financial Results and Provides Business Update
From Axcella
Via Business Wire
Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
From Axcella
Via Business Wire
Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
From Axcella
Via Business Wire
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
From Axcella
Via Business Wire
Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
From Axcella
Via Business Wire
Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125
From Axcella
Via Business Wire
Axcella Reports First Quarter Financial Results and Provides Business Update
From Axcella
Via Business Wire
Axcella to Report First Quarter 2021 Financial Results on May 6, 2021
From Axcella
Via Business Wire
Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021
From Axcella
Via Business Wire
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
From Axcella
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.